Zenapax-activated peptide immunotherapy.
Phase of Trial: Phase I
Latest Information Update: 28 Jan 2016
At a glance
- Drugs Basiliximab (Primary) ; Daclizumab; PEP-3-KLH conjugate vaccine; Temozolomide
- Indications Glioblastoma
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms ZAP IT
- 07 Jun 2017 Biomarkers information updated
- 29 Mar 2011 Planned end date changed from 1 Nov 2010 to 1 Nov 2013 as reported by ClinicalTrials.gov.
- 28 Aug 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.